GlobeNewswire

HAProxy Technologies Announces Improvements to Performance, Management, and Security for Enterprises

Dela

HAProxy Enterprise Edition 1.8r1 Adds HTTP/2, Dynamic Scaling, WAF, and Other Key Enterprise Features

BOSTON, May 02, 2018 (GLOBE NEWSWIRE) -- HAProxy Technologies, the company behind the world's fastest and most widely used software load balancer, is announcing the release of HAProxy  Enterprise Edition 1.8r1. HAProxy Enterprise Edition 1.8r1 is built on top of the monumental stable release of HAProxy 1.8 with additional enhancements that help enterprises manage and secure modern application environments across the full spectrum of today's threats.

HAProxy Enterprise Edition 1.8r1 contains a number of powerful improvements in performance and application acceleration such as support for HTTP/2, Multithreading, and Small Object Caching. There are also significant improvements in dynamic capabilities for cloud and microservices environments including Hitless Reloads, DNS for Service Discovery, Server Templates, and improved Runtime API functionality.

"This is the biggest and possibly most anticipated release of HAProxy Enterprise Edition we have ever had," said Willy Tarreau, CTO HAProxy Technologies. "I'm very proud of the whole HAProxy Technologies R&D team as well as the community contributors for their hard work in advancing HAProxy in multiple key areas including fast and secure edge and microservices delivery, while maintaining the proven reliability that it is known for."

HAProxy Enterprise Edition 1.8r1 ships with an enterprise suite which contains administration and security-focused add-ons that have the same level of high performance that users expect from HAProxy. The latest additions include a new Web Application Firewall, Stick Table Aggregator with real time, cluster-wide tracking for improved DDoS attack and bot protection, direct integration with Google reCAPTCHA, Single Sign On (SSO) support, and significant improvements to the Real Time Dashboard.

"As the company behind the world's fastest and most widely used software load balancer, we have been trusted by millions of websites to continually deliver highly secure and reliable products," said Dujko Radovnikovic, CEO HAProxy Technologies. "Our latest release strengthens this trust by providing a powerful set of new features to manage and secure modern applications while maintaining our best-in-class performance and reliability."

"We initially chose HAProxy Enterprise Edition over other software load balancers due to its performance and reliability. Since then we've worked closely with the HAProxy Technologies team to provide feedback and leverage their support. We are very excited to see the 1.8r1 release which not only includes many useful capabilities, but also incorporates many of our own feature requests," said Scott Bruce, Director of Application Architecture, dataxu.

HAProxy 1.8 and HAProxy Enterprise Edition 1.8r1 Key Enhancements:

  • HTTP/2 Support - Support for clients to communicate with the load balancer via the HTTP/2 protocol.

  • Multithreading - Splits processing across multiple threads while sharing the same memory space.

  • HTTP Small Object Caching - Caches small objects in memory.

  • Hitless Reloads - Reloads of HAProxy do not lose any connections for upgrades or changes to the configuration.

  • DNS for Service Discovery - Dynamically scales the number of backend servers by querying the service registry over DNS. Maintains the IP address, port, and weight of the servers within HAProxy.

  • Server Templates - Enables the provisioning of multiple backend servers with a single server line to be filled in during runtime.

  • Improved Runtime API - Gives the ability to pull statistics and information from HAProxy or to dynamically configure it during runtime.

Exclusive HAProxy Enterprise Edition 1.8r1 Key Enhancements:

  • WAF Module - A high-performance Web Application Firewall which supports both whitelist based and blacklist based rulesets, ensuring a very high level of protection for even the most insecure web applications.

  • Stick Table Aggregator - Combines values from stick tables across multiple processes or servers which allows for real time cluster-wide tracking of any characteristic of a request.

  • reCAPTCHA Module - Enables presenting anomalous clients with Google reCAPTCHA v2 challenges which can protect websites from bots and other types of automated threats while letting real users pass through with ease.

  • SSO Module - Enables the implementation of SSO (Single Sign On) on a Microsoft Active Directory domain.

  • Real Time Dashboard - Provides management capabilities and an aggregated view of service activity and status which updates and graphs in real time, with visual alerting when values reach defined thresholds.

For more information on everything new in HAProxy Enterprise Edition 1.8r1, you can watch the on-demand webinar at What's New in HAProxy Enterprise Edition 1.8r1

About HAProxy Enterprise Edition

HAProxy Enterprise Edition is an enterprise-class version of HAProxy that includes a robust and cutting-edge code base, enterprise suite of add-ons, expert support, and professional services. At its core, it incorporates feature backports from the HAProxy development branch for customers who require immediate access to the latest functionality in a hardened version of code.

About HAProxy Technologies

HAProxy Technologies is the company behind HAProxy, the world's fastest and most widely used software load balancer. High-profile websites including Booking.com, GitHub, Reddit, StackOverflow, Tumblr, Vimeo and Yelp choose HAProxy to deliver websites and applications with high availability, performance, and security at any scale. Trusted by leading cloud providers such as Amazon Web Services, Rackspace, Red Hat OpenShift, and OpenStack, HAProxy sets the standard for superior application delivery. HAProxy Technologies is headquartered in Waltham, MA, with offices in France and Croatia. For more information on HAProxy, support, and enterprise solutions, visit: www.haproxy.com. You can also follow @HAProxy on Twitter or visit us on LinkedIn and Facebook for more information about HAProxy.

Media Contact

Company Name: HAProxy Technologies
Email Address: press@haproxy.com Website: www.haproxy.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: HAProxy Technologies via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum